Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction ...

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously ...